These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11304902)

  • 1. Effect of alosetron on the pharmacokinetics of alprazolam.
    D'Souza DL; Levasseur LM; Nezamis J; Robbins DK; Simms L; Koch KM
    J Clin Pharmacol; 2001 Apr; 41(4):452-4. PubMed ID: 11304902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of alosetron on the pharmacokinetics of fluoxetine.
    D'Souza DL; Dimmitt DC; Robbins DK; Nezamis J; Simms L; Koch KM
    J Clin Pharmacol; 2001 Apr; 41(4):455-8. PubMed ID: 11304903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers.
    Markowitz JS; Donovan JL; Devane CL; Taylor RM; Ruan Y; Wang JS; Chavin KD
    Clin Pharmacol Ther; 2003 Dec; 74(6):536-42. PubMed ID: 14663456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme.
    Markowitz JS; Donovan JL; DeVane CL; Taylor RM; Ruan Y; Wang JS; Chavin KD
    JAMA; 2003 Sep; 290(11):1500-4. PubMed ID: 13129991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics and pharmacokinetics of oral contraceptives co-administered with alosetron (Lotronex).
    Koch K; Campanella C; Baidoo CA; Manzo JA; Ameen VZ; Kersey KE
    Dig Dis Sci; 2004 Aug; 49(7-8):1244-9. PubMed ID: 15387353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
    Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM
    Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of alosetron on theophylline pharmacokinetics.
    Koch KM; Ricci BM; Hedayetullah NS; Jewell D; Kersey KE
    Br J Clin Pharmacol; 2001 Nov; 52(5):596-600. PubMed ID: 11736869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alosetron and irritable bowel syndrome.
    Mayer EA; Bradesi S
    Expert Opin Pharmacother; 2003 Nov; 4(11):2089-98. PubMed ID: 14596662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.
    Houghton LA; Foster JM; Whorwell PJ
    Aliment Pharmacol Ther; 2000 Jun; 14(6):775-82. PubMed ID: 10848662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride.
    Miller DP; Alfredson T; Cook SF; Sands BE; Walker AM
    Am J Gastroenterol; 2003 May; 98(5):1117-22. PubMed ID: 12809837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology and clinical experience with alosetron.
    Camilleri M
    Expert Opin Investig Drugs; 2000 Jan; 9(1):147-59. PubMed ID: 11060667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alosetron.
    Balfour JA; Goa KL; Perry CM
    Drugs; 2000 Mar; 59(3):511-8; discussion 519-20. PubMed ID: 10776833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients.
    Gupta SK; Kunka RL; Metz A; Lloyd T; Rudolph G; Perel JM
    J Clin Pharmacol; 1995 Feb; 35(2):202-7. PubMed ID: 7751433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: clinical pharmacology of alosetron.
    Gunput MD
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():70-6. PubMed ID: 10429744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
    Krause R; Ameen V; Gordon SH; West M; Heath AT; Perschy T; Carter EG
    Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.
    Cremonini F; Delgado-Aros S; Camilleri M
    Neurogastroenterol Motil; 2003 Feb; 15(1):79-86. PubMed ID: 12588472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome.
    Viramontes BE; Camilleri M; McKinzie S; Pardi DS; Burton D; Thomforde GM
    Am J Gastroenterol; 2001 Sep; 96(9):2671-6. PubMed ID: 11569693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism.
    Yasui N; Otani K; Kaneko S; Ohkubo T; Osanai T; Sugawara K; Chiba K; Ishizaki T
    Clin Pharmacol Ther; 1996 May; 59(5):514-9. PubMed ID: 8646822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects.
    Chen L; Boinpally R; Gad N; Greenberg WM; Wangsa J; Periclou A; Ghahramani P
    Clin Drug Investig; 2015 Oct; 35(10):601-12. PubMed ID: 26315684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors.
    Koch KM; Corrigan BW; Manzo J; James CD; Scott RJ; Stead AG; Kersey KE
    Aliment Pharmacol Ther; 2004 Jul; 20(2):223-30. PubMed ID: 15233703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.